Title: livre-docente
E-mail: [email protected]
Lattes: 2458188374782290http://lattes.cnpq.br/2458188374782290
Orcid: 0000-0001-7168-590 https://orcid.org/0000-0001-7168-5906
Scopus: 57221695832 https://www.scopus.com/authid/detail.uri?authorId=57221695832
Google Scholar: https://scholar.google.com.br/citations?user=7zL6V4kAAAAJ&hl=pt-BR
Research ID: GRY-0453-2022 https://www.webofscience.com/wos/author/record/33320671
Research line
Effectiveness and complications of immunosuppressive treatment in patients with inflammatory arthritis.
Summary
The line of research evaluates the effectiveness, predictors and complications of treatments in rheumatologic patients, mainly with inflammatory arthritis, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. The use of immunobiological agents, conventional immunosuppressants and corticosteroid therapy is evaluated through the analysis of longitudinal inception cohorts, with an emphasis on drug survival, mechanisms of action, response predictors and medication withdrawal strategies. Furthermore, treatment complications are evaluated, such as infusion reactions and infections. Strategies to reduce infectious risk are studied, such as vaccination and other preventive approaches. The line of research evaluates the safety, immunogenicity and effectiveness of vaccines from different platforms, as well as strategies to optimize the vaccine response, such as the impact of temporarily interrupting immunosuppressants after vaccination.
Main Publications:
- Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG, Rojo PT, Pereira RMR, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Ribeiro CT, Deveza GBH, Martins VAO, Silva CA, Lopes MH, Duarte AJS, Antonangelo L, Sabino EC, Kallas EG, Pasoto SG, Bonfa E. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021;27(10):1744-1751. (Fator de Impacto 87.241).
- Aikawa NE, Kupa LVK, Pasoto SG, Medeiros-Ribeiro AC, Yuki EFN, Saad CGS, Pedrosa T, Fuller R, Shinjo SK, Sampaio-Barros PD, Andrade DCO, Pereira RMR, Seguro LPC, Valim JML, Waridel F, Sartori AMC, Duarte AJS, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CA, Bonfa E. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatol. 2022;4(2):e113-e124. (Fator de Impacto 35.482).
- Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, da Silva HC, Saad, CGS , Yuki EFN, Pasoto SG, Araujo CSR, Nakai TL, Silva CA, Pedrosa T, Kupa LVK, Silva MSR, Balbi GGM, Kallas EG, Aikawa NE, Bonfa E. Distinct Impact df DMARD Combination and Monotherapy in Immunogenicity of an Inactivated Sars-Cov-2 Vaccine in Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 2022; 81; 710-719.(Fator de Impacto: 27.993).
- Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Silva MSR, Yuki EFN, Pasoto SG, Pedrosa T, Kupa LVK, Zou G, Pereira RMR, Silva CA, Aikawa NE, Bonfa E. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Ann Rheum Dis. 2022 Jun;81(6):889-897. (Fator de Impacto: 27.993).
- Ribeiro ACM, Guedes LKN, Moraes JCB, Saad CGS, Aikawa NE, Calich ALG, Franca ILA, Carvalho JF, Sampaio-Barros PD, Gonçalves CR, Borba EF, Timenetsky MCST, Precioso AR, Duarte A, Bonfá E, Laurindo IMM. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. 2011. Annals of the Rheumatic Diseases; 70; 2144-2147. (Fator de Impacto: 27.993).
PROJETOS ORIENTADOR/ LINHA
Linha 6. SISTEMA IMUNE E AUTOIMUNE
PROJETO ANA CRISTINA: ESTUDOS DE IMUNOGENICIDADE E EFETIVIDADE DA VACINAÇÃO C ONTRA SARS-COV-2 EM PACIENTES COM ARTROPATIAS INFLAMATÓRIAS.
PROJETO ANA CRISTINA: ESTUDOS DE SEGURANÇA, EFETIVIDADE E PREDITORES DE RESPOSTA A AGENTES IMUNOBIOLÓGICOS EM PACIENTES COM ARTROPATIAS INFLAMATÓRIAS.